A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients
Information source: Abbott
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obesity
Intervention: Sibutramine hydrochloride (Drug); Placebo (Drug); Sibutramine hydrochloride (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Abbott Official(s) and/or principal investigator(s): Cheryl Renz, MD, Study Director, Affiliation: Abbott
Summary
The purpose of the study was to determine the long-term effect of sibutramine treatment on
cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
Clinical Details
Official title: Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Risk of Experiencing a Primary Outcome Event (POE) (i.e., Nonfatal Myocardial Infarction [MI], Nonfatal Stroke, Resuscitated Cardiac Arrest, Cardiovascular [CV] Death)
Secondary outcome: Risk of Death From Any Cause (All-cause Mortality)Risk of Experiencing a POE or a Revascularization Procedure Risk of Experiencing a Nonfatal MI Included in the POE Risk of Experiencing a Nonfatal Stroke Included in the POE Risk of Experiencing a Resuscitated Cardiac Arrest Included in the POE Risk of Experiencing Cardiovascular Death Included in the POE
Detailed description:
The study consisted of 4 periods: 1) a Screening Period of approximately 2 weeks; 2) a
6-week Lead-in Period, during which subjects received single-blind sibutramine and
country-specific standard of care for weight management. Subjects who discontinued study
drug treatment during the Lead-in Period were not randomized and did not participate in the
double-blind Treatment Period or the Follow-up Period; 3) a double-blind Treatment Period in
which subjects were randomized to 1 of the 2 treatment groups and were followed until the
study ended; and 4) a double-blind Follow-up Period, during which randomized subjects who
discontinued study drug were followed until the study ended. The Randomization Phase
consisted of the double-blind Treatment Period and the double-blind Follow-up Period.
Subjects received country-specific standard of care for weight management during the
Randomization Phase.
An independent events adjudication committee evaluated all potential cardiovascular outcome
events and confirmed the outcome events and time of onset to be included in the statistical
analyses.
Eligibility
Minimum age: 55 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subject's body mass index (BMI) was >= 27 kg/m(2) and <= 45 kg/m(2) or their BMI was
>= 25 kg/m(2) and < 27 kg/m(2) with waist circumference of >= 102 cm in males or >=
88 cm in females.
- Medical history positive for:
- Preexisting cardiovascular disease (i. e., coronary artery disease,
cerebrovascular disease, or peripheral arterial occlusive disease) and/or
- Type 2 diabetes mellitus with at least 1 other risk factor (i. e., dyslipidemia,
controlled hypertension, current smoker, or diabetic nephropathy with evidence
of microalbuminuria)
Exclusion Criteria:
- History of recent myocardial infarction.
- Heart failure symptoms greater than New York Heart Association Functional Class II.
- Hemodynamically significant valvular or left ventricular (LV) tract obstruction.
- Subjects without a pacemaker and with any of the following:
- Sinus bradycardia (< 50 bpm)
- Sick sinus syndrome
- Atrioventricular block of more than 1st degree
- Mean sitting systolic blood pressure (SBP) > 160 mmHg. Mean sitting diastolic
blood pressure (DBP) > 100 mmHg. Mean sitting heart rate (HR) > 100 bpm.
- Syncopal episodes presumed to be due to uncontrolled life-threatening
arrhythmias.
- Planned cardiac surgery or coronary angioplasty within 6 months of screening.
- History of recent non-hemorrhagic stroke or transient ischemic attack (TIA), history
of hemorrhagic stroke.
- Hyperthyroidism.
- Known chronic liver disease or endstage renal disease.
- Severe, symptomatic benign prostatic hyperplasia which may require surgery.
- Known pheochromocytoma, history of narrow angle glaucoma, Gilles de la Tourette
syndrome, history of seizures, history of bariatric or abdominal obesity surgery
(excluding liposuction).
- Concomitant use of monoamine oxidase inhibitors or drugs that increase levels of
serotonin in the brain.
- Treated hypertension stabilized for less than 3 months.
- Inability to perform regular physical activity.
Locations and Contacts
Global Medical Services, North Chicago, Illinois 60064, United States
Additional Information
package insert information
Starting date: January 2003
Last updated: May 6, 2010
|